Form 4: Hologic Insider Reports Merger-Related Transactions

Hologic Inc. insider Benjamin Jordan Cohn reports on transactions related to the company's merger, including the conversion of stock options and performance units.

Summary

• Benjamin Jordan Cohn, an officer and Principal Accounting Officer of Hologic Inc., has filed a Form 4 detailing transactions related to the company's merger.
• The filing indicates that as of April 7, 2026, Cohn acquired 17,964 shares of common stock, with 80 shares acquired through an employee stock purchase plan.
• The merger agreement, dated October 21, 2025, involved Hologic, Hopper Parent Inc., and Hopper Merger Sub Inc., resulting in Hologic becoming a wholly owned subsidiary of Parent.
• At the effective time of the merger, each share of Hologic common stock was converted into $76.00 in cash and one contingent value right (CVR) potentially worth up to $3.00.
• Time-vesting restricted stock units (RSUs) held by Cohn converted into the right to receive the merger consideration.
• Performance stock units (PSUs) also converted, with performance goals deemed achieved at the greater of target or actual levels.
• All outstanding stock options were cancelled and converted into cash payments or CVRs, depending on their exercise price relative to the merger consideration.
• As a result of the merger, Cohn no longer beneficially owns any shares of Hologic common stock directly or indirectly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing, as it confirms the execution of a merger that provides cash and potential upside to shareholders and insiders, though the CVR introduces some uncertainty.

Positives

• The merger consideration of $76.00 per share in cash plus a CVR provides a significant payout to shareholders.
• The conversion of stock options and RSUs into cash and CVRs offers immediate value realization for holders.
• Performance stock units were deemed achieved at favorable levels, maximizing potential payouts.

Negatives

• The company is being acquired and will become a wholly owned subsidiary, indicating a change in corporate structure and potential delisting.
• The contingent value right (CVR) introduces uncertainty regarding the full value shareholders will ultimately receive.

Risks

• The contingent value right (CVR) is subject to future conditions and may not result in the full $3.00 payout.
• The merger itself carries integration risks and potential disruptions to business operations.
• Options with exercise prices above the cash consideration or cash plus CVR value were cancelled for no consideration.

Future Outlook

The future outlook for Hologic as an independent entity is concluded due to its acquisition. The primary future financial consideration for former shareholders and option holders lies in the potential payout of the contingent value rights (CVRs).

Management Comments

• The filing details the conversion of various equity awards into cash and contingent value rights as per the merger agreement.
• It clarifies that as a result of the merger, the reporting person no longer beneficially owns any shares of Company Common Stock.

Industry Context

StockSavvy.ai notes that this Form 4 filing reflects a significant event in the life cycle of a public company – an acquisition. The structure of the deal, including cash, stock options, RSUs, PSUs, and a contingent value right, is typical for such transactions, aiming to provide value to shareholders while incentivizing management and retaining key personnel through the transition.

Comparison to Industry Standards

• The merger consideration of $76.00 per share in cash plus a CVR is a common structure in technology and healthcare acquisitions, aiming to capture upside potential.
• The treatment of stock options and RSUs, where those with exercise prices below the cash consideration are cashed out and others receive CVRs, aligns with industry practices to ensure value is distributed equitably based on the intrinsic value of the awards.
• The certification of performance goals for PSUs at the greater of target or actual levels is a standard mechanism to ensure that performance-based compensation is awarded fairly in the context of a merger.

Stakeholder Impact

• Shareholders: Will receive $76.00 per share in cash plus a contingent value right, representing a significant return on investment.
• Employees (including management): Equity awards have been converted into cash and/or contingent value rights, providing financial realization.
• Creditors: The acquisition by a parent entity may alter the debt structure and covenants, but the immediate impact is likely neutral unless specific terms are affected.

Next Steps

• Shareholders will await the outcome of the contingent value right (CVR) to determine the final total consideration received.
• Hologic Inc. will continue operations as a wholly owned subsidiary of Parent.

Key Dates

Recommendation

This filing is a Form 4 reporting insider transactions related to a completed merger. The price sensitivity is high due to the confirmation of merger terms and payouts. However, as the merger is complete and the company is being taken private, a 'hold' recommendation is appropriate for existing shareholders who have received or will receive the merger consideration. New investment decisions would depend on the acquiring entity's future plans and the performance of the CVR.

Keywords

Hologic Inc., HOLX, Form 4, Insider Transaction, Merger, Acquisition, Stock Options, Restricted Stock Units, Performance Stock Units, Contingent Value Right, Benjamin Jordan Cohn, SEC Filing